Compare RBCAA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | PGEN |
|---|---|---|
| Founded | 1974 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1998 | 2013 |
| Metric | RBCAA | PGEN |
|---|---|---|
| Price | $74.21 | $4.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 73.8K | ★ 5.4M |
| Earning Date | 01-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | $230,981,000.00 |
| Revenue This Year | $3.93 | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | $95.69 | ★ N/A |
| Revenue Growth | ★ 8.50 | N/A |
| 52 Week Low | $61.62 | $1.23 |
| 52 Week High | $78.00 | $5.47 |
| Indicator | RBCAA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.91 | 53.07 |
| Support Level | $67.08 | $3.31 |
| Resistance Level | $75.91 | $4.44 |
| Average True Range (ATR) | 1.80 | 0.34 |
| MACD | 0.53 | 0.07 |
| Stochastic Oscillator | 83.45 | 71.43 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.